Figure 4: Proteome changes in MCF7 and LCC2 cell lines following 4-OHT and fulvestrant treatment.
From: Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer
Proteome changes in LCC2 and MCF7 to (a) 4-OHT and (b) fulvestrant showing overlapping set of 6,470 quantified proteins. Similarly, proteome changes in (c) MCF7 and (d) LCC2 to 4-OHT and fulvestrant. Cells were treated with vehicle, 10 nM of 4-OHT or fulvestrant for 3 days, and whole-cell lysates were analysed. Values are the mean of duplicates, and the numbers (n=) denote the number of changed proteins (see Supplementary Fig. S13 for replicate consistency). (e) Connection of changed proteins by 4-OHT and fulvestrant in MCF7 and LCC2 to E2- and RA-regulated genes, and to ER- and RARA-binding sites. (f) Percentage of the changed proteins following 4-OHT and fulvestrant treatment, or the whole data set, which are E2- and RA-regulated or have ER- and RARA-binding sites in genomic proximity.
